Parkinson's disease severity and use of dopaminergic medications

NINDS NET-PD Investigators

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The effects of dopaminergic therapy in parkinson's disease (PD) can vary depending on the class of medication selected. Objective: The aim of this post hoc study was to determine if the class of dopaminergic therapy correlated with disease severity in persons with early, treated PD. Methods: A non-parametric global statistical test (GST) was used to assess the status of participants treated with dopamine agonist (DA) monotherapy, levodopa (LD) monotherapy or combined LD and DA therapy on multiple PD outcomes encompassing motor, cognitive, psychiatric and autonomic function, as well as disability and quality of life. Results: The outcomes measured at the beginning of the study showed lower disease burden for participants on initial DA monotherapy compared to those taking combined LD and DA therapy after controlling for age, education, taking cog-meds and amantadine. Conclusion: This observation suggests that clinicians treating early PD patients favor combined LD and DA therapy in patients with more disabling features over DA monotherapy. As such, studies of PD progression in treated PD patients may be affected by the class of symptomatic dopaminergic therapy.

Original languageEnglish (US)
Pages (from-to)297-299
Number of pages3
JournalParkinsonism and Related Disorders
Volume21
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Dopamine Agonists
Parkinson Disease
Levodopa
Therapeutics
Amantadine
Psychiatry
Disease Progression
Quality of Life
Education

Keywords

  • Clinical trial
  • Cognition
  • Disability
  • Dopamine agonist
  • Levodopa
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology

Cite this

Parkinson's disease severity and use of dopaminergic medications. / NINDS NET-PD Investigators.

In: Parkinsonism and Related Disorders, Vol. 21, No. 3, 01.03.2015, p. 297-299.

Research output: Contribution to journalArticle

NINDS NET-PD Investigators. / Parkinson's disease severity and use of dopaminergic medications. In: Parkinsonism and Related Disorders. 2015 ; Vol. 21, No. 3. pp. 297-299.
@article{3f48429b3cc74da88165c3e19bdf3940,
title = "Parkinson's disease severity and use of dopaminergic medications",
abstract = "Background: The effects of dopaminergic therapy in parkinson's disease (PD) can vary depending on the class of medication selected. Objective: The aim of this post hoc study was to determine if the class of dopaminergic therapy correlated with disease severity in persons with early, treated PD. Methods: A non-parametric global statistical test (GST) was used to assess the status of participants treated with dopamine agonist (DA) monotherapy, levodopa (LD) monotherapy or combined LD and DA therapy on multiple PD outcomes encompassing motor, cognitive, psychiatric and autonomic function, as well as disability and quality of life. Results: The outcomes measured at the beginning of the study showed lower disease burden for participants on initial DA monotherapy compared to those taking combined LD and DA therapy after controlling for age, education, taking cog-meds and amantadine. Conclusion: This observation suggests that clinicians treating early PD patients favor combined LD and DA therapy in patients with more disabling features over DA monotherapy. As such, studies of PD progression in treated PD patients may be affected by the class of symptomatic dopaminergic therapy.",
keywords = "Clinical trial, Cognition, Disability, Dopamine agonist, Levodopa, Parkinson's disease",
author = "{NINDS NET-PD Investigators} and Fang, {John Y.} and Adriana P{\'e}rez and Christine, {Chadwick W.} and Maureen Leehey and Aminoff, {Michael J.} and Boyd, {James T.} and Morgan, {John C.} and Rohit Dhall and Nicholas, {Anthony P.} and Ivan Bodis-Wollner and Zweig, {Richard M.} and Goudreau, {John L.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.parkreldis.2014.10.016",
language = "English (US)",
volume = "21",
pages = "297--299",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Parkinson's disease severity and use of dopaminergic medications

AU - NINDS NET-PD Investigators

AU - Fang, John Y.

AU - Pérez, Adriana

AU - Christine, Chadwick W.

AU - Leehey, Maureen

AU - Aminoff, Michael J.

AU - Boyd, James T.

AU - Morgan, John C.

AU - Dhall, Rohit

AU - Nicholas, Anthony P.

AU - Bodis-Wollner, Ivan

AU - Zweig, Richard M.

AU - Goudreau, John L.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background: The effects of dopaminergic therapy in parkinson's disease (PD) can vary depending on the class of medication selected. Objective: The aim of this post hoc study was to determine if the class of dopaminergic therapy correlated with disease severity in persons with early, treated PD. Methods: A non-parametric global statistical test (GST) was used to assess the status of participants treated with dopamine agonist (DA) monotherapy, levodopa (LD) monotherapy or combined LD and DA therapy on multiple PD outcomes encompassing motor, cognitive, psychiatric and autonomic function, as well as disability and quality of life. Results: The outcomes measured at the beginning of the study showed lower disease burden for participants on initial DA monotherapy compared to those taking combined LD and DA therapy after controlling for age, education, taking cog-meds and amantadine. Conclusion: This observation suggests that clinicians treating early PD patients favor combined LD and DA therapy in patients with more disabling features over DA monotherapy. As such, studies of PD progression in treated PD patients may be affected by the class of symptomatic dopaminergic therapy.

AB - Background: The effects of dopaminergic therapy in parkinson's disease (PD) can vary depending on the class of medication selected. Objective: The aim of this post hoc study was to determine if the class of dopaminergic therapy correlated with disease severity in persons with early, treated PD. Methods: A non-parametric global statistical test (GST) was used to assess the status of participants treated with dopamine agonist (DA) monotherapy, levodopa (LD) monotherapy or combined LD and DA therapy on multiple PD outcomes encompassing motor, cognitive, psychiatric and autonomic function, as well as disability and quality of life. Results: The outcomes measured at the beginning of the study showed lower disease burden for participants on initial DA monotherapy compared to those taking combined LD and DA therapy after controlling for age, education, taking cog-meds and amantadine. Conclusion: This observation suggests that clinicians treating early PD patients favor combined LD and DA therapy in patients with more disabling features over DA monotherapy. As such, studies of PD progression in treated PD patients may be affected by the class of symptomatic dopaminergic therapy.

KW - Clinical trial

KW - Cognition

KW - Disability

KW - Dopamine agonist

KW - Levodopa

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84923261330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923261330&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2014.10.016

DO - 10.1016/j.parkreldis.2014.10.016

M3 - Article

C2 - 25541182

AN - SCOPUS:84923261330

VL - 21

SP - 297

EP - 299

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 3

ER -